Independent Review of E2100: A Phase III Trial of Bevacizumab Plus Paclitaxel Versus Paclitaxel in Women With Metastatic Breast Cancer

PURPOSE: E2100, an open-label, randomized, phase III trial conducted by the Eastern Cooperative Oncology Group (ECOG), demonstrated a significant improvement in progression-free survival (PFS) and overall response rate (ORR) with paclitaxel plus bevacizumab compared with paclitaxel alone as initial...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gray, Robert, Bhattacharya, Suman, Bowden, Christopher, Miller, Kathy, Comis, Robert L.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2009
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2799052/
https://ncbi.nlm.nih.gov/pubmed/19720913
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.21.6630
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados